| QLK3-2001-00090 |
Stable extracellular matrices
as novel biotherapeutics for biomimetic induction of hard
tissue growth (MATRIX) |
| QLK3-2001-00093 |
Biochemical and functional
characterisation of antigen-presenting cell-derived exosomes:
The design of a cell-free cancer vaccine (EXOSOME) |
| QLK3-2001-00225 |
Innovative therapeutics
for the prototype autoimmune disease, myasthenia gravis (Immunotherapeutics) |
| QLK3-2001-00244 |
Novel in vitro testing
platforms based on intra- and extracellular sensing (CellSens) |
| QLK3-2001-00277 |
Development of novel anti-bacterials
and anti-infectives that target programmed bacterial cell
death (BAS anti-microbials) |
| QLK3-2001-00283 |
Integrated in vitro and in
vivo testing of drugs in prion diseases: screening,
development and mechanisms of novel therapeutics (STOPTSEs) |
| QLK3-2001-00305 |
Deoxyuridine triphosphate
nucleotidohydrolase as drug target for the control of protozoal
and bacterial infections (dUTPase) |
| QLK3-2001-00401 |
Prevalidation of novel
alternative pharma-/toxicological screening based on yeast
expression technology (MULTIPLEX) |
| QLK3-2001-00407 |
Organotypic brain slice
cultures as an alternative to in vivo experimentation
in the study of brain repair mechanisms (ORCA) |
| QLK3-2001-00422 |
Targeting heme-oxygenase-1
or downstream processes: A new therapeutic approach for treatment
of inflammation (HO-1) |
| QLK3-2001-00427 |
Gene therapy of hematopoietic
stem cells for inherited diseases (INHERINET) |
| QLK3-2001-00498 |
Therapeutic molecules for
modulation of ligand-receptor mediated apoptosis (Triskel) |
| QLK3-2001-00506 |
Research, selection and
mechanism of action of potential therapeutic agents against Flaviviridae (Hepatitis
C virus, Dengue virus, West Nile virus) (Flavitherapeutics) |
| QLK3-2001-01104 |
Novel therapeutic tools
and strategies to fight polycystic kidney disease (GTPKD) |
| QLK3-2001-01982 |
Novel gene chip technology
for simplified detection of molecularly heterogeneous genetic
diseases: Detection of cystic fibrosis as a model (CF-CHIP) |
| QLK3-2001-02166 |
A Fusion Gene for the Treatment
of Cancer (Scavidin) |
| QLK3-2002-01772 |
Blood grouping and genotyping:
Improving patient safety and blood transfusion compatibility
(BloodGen) |
| QLK3-2002-01775 |
Demonstration of the clinical
utility of holoTC as an early marker of vitamin B12 deficiency
(HoloTC) |
| QLK3-2002-01777 |
Generation of bioengineered
pancreatic islet micro-organs for insulin replacement therapy
in diabetes mellitus (Pseudoislet) |
| QLK3-2002-01918 |
Evaluation of the facilitation
of umbilical cord blood transplant engraftment using ex vivo
haematopoietic progenitors/stem cell expansion (EUROCORD
III) |
| QLK3-2002-01936 |
Predicting outcome and
developing new therapeutic strategies for haematological
stem cell transplant recipients using in vitro techniques
(TRANSEUROPE) |
| QLK3-2002-01949 |
Integrated strategy for
efficient therapeutic retrovirus production based on modular
cell lines (InsertAGene) |
| QLK3-2002-01955 |
Therapeutic strategies
using VEGF substitutes and gene therapies to maintain the
integrity of the arterial wall (VEGF Strategies) |
| QLK3-2002-01956 |
Interplay among mitochondria
and p53 family proteins during apoptosis induced by DNA damage:
A new strategy for cancer therapy (IMPALED) |
| QLK3-2002-01980 |
Development of an immunotherapy
for breast cancer based on dendritic cells by developing
and comparing different types of tumour-specific immunogens
(Cancer Immutherapy) |
| QLK3-2002-01997 |
Novel GENE DRUG strategy
based on hybridisation of functional entities to plasmids
(EURO GENE DRUG) |
| QLK3-2002-02003 |
European standard operating
procedures for electrochemotherapy and electrogenetherapy
(ESOPE) |
| QLK3-2002-02010 |
A prime boost strategy
for immunotherapy of breast and ovarian cancer (Prime Boost
Ca Vaccine) |
| QLK3-2002-02017 |
Clearance of apoptotic
cells: Discovery of autoantigens and therapy for autoimmune
diseases (APOCLEAR) |
| QLK3-2002-02026 |
Allergen-derived DNA vaccines:
Mechanisms involved in mouse and human models (ALLDNAVAC) |
| QLK3-2002-02029 |
Synthesis and mechanism
of action of novel classes of retinoids and rexinoids with
antineoplastic activities |
| QLK3-2002-02031 |
Neuropeptides for lung
treatment of rare lung diseases, primary and secondary pulmonary
hypertension (Neuropeotide Lung Therapy) |
| QLK3-2002-02039 |
Engineered mesenchymal
stem cells combined with gene therapy for osteoarticular
diseases (STEMGENOS) |
| QLK3-2002-02049 |
Heparanase inhibitors in
antiangiogenic and antimetastatic cancer therapy (HEPARANASE) |
| QLK3-2002-02052 |
Semliki Forest virus based
therapeutic systems (SFVECTORS) |
| QLK3-2002-02059 |
Targeting signals essential
for angiogenesis: Gene therapy to prevent new vessel formation
and to induce apoptosis and necrosis of tumour vasculature
(anti-tumour angiogenesis) |
| QLK3-2002-02062 |
The alternative splicing
database – A novel tool to diagnose human disease (ASD) |
| QLK3-2002-02114 |
European network to develop
new therapeutic strategies for Parkinson's Disease using
lentiviral vector technology ((N)EUROPARK) |
| QLK3-2002-02119 |
Development and application
of chromosome-based gene transfer vectors for cell therapy
(Chromosome therapy) |
| QLK3-2002-02127 |
Demonstrating the applicability
of novel indices of immunological tolerance to clinical practice
using immunosuppression-free transplant recipients (Indices
of tolerance) |
| QLK3-2002-02136 |
Profiling metalloproteinase
inhibition for tumour therapy |
| QLK3-2002-02149 |
Anchored cAMP signaling – implications
for treatment of human disease (cAMP signalling) |
